SCHEDULE 13D/A 0001224962 XXXXXXXX LIVE 7 Common Stock, par value $0.001 per share 01/26/2026 false 0001454789 04635X102 Astria Therapeutics, Inc.

22 Boston Wharf Road 10th Floor Boston MA 02210

Alexander Rakitin (646) 205-5340 51 Astor Place, 10th Floor New York NY 10003 0001224962 N Perceptive Advisors LLC AF N DE 0 0 0 0 0 N 0 IA 0001164426 N Joseph Edelman AF N X1 0 0 0 0 0 N 0 IN 0001249675 N Perceptive Life Sciences Master Fund, Ltd. WC N E9 0 0 0 0 0 N 0 CO 0001757940 N Perceptive Xontogeny Venture Fund, L.P. WC N DE 0 0 0 0 0 N 0 CO Common Stock, par value $0.001 per share Astria Therapeutics, Inc. 22 Boston Wharf Road 10th Floor Boston MA 02210 The Reporting Persons' beneficial ownership in the Issuer changed as a result of the consummation of the previously announced acquisition of the Issuer by BioCryst pursuant to the Merger Agreement . The Merger was completed on January 23, 2026, and the Issuer ceased to exist as a separate entity. As a result of the merger, the Reporting Persons no longer beneficially owns any shares of the Issuer. The information set forth in rows 11 and 13 of the cover pages to this Schedule 13D is incorporated by reference. The information set forth in rows 7 through 10 of the cover pages to this Schedule 13D is incorporated by reference. The information set forth in Item 4 of this Schedule 13D is incorporated by reference. The information set forth in Item 4 of this Schedule 13D is incorporated by reference. Perceptive Advisors LLC /s/ Joseph Edelman 02/09/2026 Joseph Edelman /s/ Joseph Edelman 02/09/2026 Perceptive Life Sciences Master Fund, Ltd. /s/ Joseph Edelman 02/09/2026 Perceptive Xontogeny Venture Fund, L.P. /s/ Joseph Edelman 02/09/2026